
American Association for Cancer Research
- AbstractHepatocellular carcinoma (HCC) is a highly lethal malignancy with rapid onset of drug resistance and high recurrence rate, partly driven by cancer stem cells (CSC). In this study, we identified a small GTPases SEPTIN7 as a critical regulator of tumorigenesis and therapeutic resistance in HCC. SEPTIN7 was significantly upregulated in human HCC samples with high […]
- AbstractCancer treatment using immune checkpoint blockade (ICB) with anti–programmed cell death protein 1 (αPD-1) and anti–cytotoxic T lymphocyte–associated protein 4 (αCTLA-4) has been successful. However, primary and acquired resistance limits clinical benefit. To improve the effectiveness of ICB therapies, strategies that reorchestrate antitumor immunity through mechanism-based drug combinations are being actively explored. The alkylating chemotherapeutic […]
- AbstractHigh-grade serous (tubo-ovarian) carcinoma (HGSC) is the most lethal gynecologic malignancy and the most common form of ovarian cancer. Most patients (75%) are diagnosed at advanced disease stages, with widespread peritoneal dissemination leading to a poor prognosis. In this study, we characterized the interactions between fibroblasts and immune cells that facilitate the formation of a […]
- Airway hillocks are specialized, stratified squamous epithelial structures featuring luminal barrier cells supported by a dedicated basal stem cell population. In this issue of Cancer Research, Izzo and colleagues identify a distinct population of slow-cycling KRT13+ hillock-like tumor cells in lung squamous cell carcinoma, a cell state conserved across multiple squamous cell carcinoma (SCC) models. […]
- AbstractImmune evasion driven by the tumor microenvironment is a major obstacle to effective immunotherapy in gastric cancer. To overcome this barrier, a detailed understanding of the mechanisms by which gastric cancer circumvents antitumor immunity is essential. In this study, we identified KDM5B as a pivotal epigenetic–metabolic orchestrator of immune evasion in gastric cancer. Clinically, KDM5B […]
- AbstractPurpose:More than 50% of patients with non–muscle-invasive bladder cancer experience recurrence, requiring lifelong surveillance with repeated cystoscopy. Given the invasive nature and cost of cystoscopy, accurate noninvasive tools are needed to support risk-adapted monitoring. We evaluated the ability of Oncuria-Monitor, a multiplex urine biomarker assay, to detect recurrent bladder cancer during surveillance.Patients and Methods:Between February […]
- In the original version of this article (1), there was an error in the Patients and Methods section. The idarubicin dose in cycle 2 of the IA regimen should be 8 mg/m2 on days 1 to 3 and not 100 mg/m2 on days 1 to 3. The error has been corrected in the latest online […]
- AbstractPurpose:Liquid biopsy monitoring in pediatric solid tumors is limited by low mutational burden and lack of trackable genomic drivers. We sought to develop a mutation-agnostic, methylation-based liquid biopsy framework enabling universal molecular surveillance of high-risk neuroblastoma.Experimental Design:Using whole-genome Oxford Nanopore Technologies sequencing of high-risk neuroblastoma tumors, we compared tumor-derived methylation profiles with a comprehensive atlas […]
- AbstractPurpose:Outcomes in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remain discouraging despite the rapid expansion of treatment paradigms over the past decade. Clinicians must often decide between conventional salvage treatment regimens or enrollment in clinical trials.Experimental Design:We retrospectively identified 657 patients with AML in second treatment salvage and compared the outcomes of those who […]
- AbstractTargeted radionuclide therapy (TRT) is an emerging modality in oncology that delivers internal radiation specifically to tumor sites. It typically consists of a particle-emitting radionuclide, a linking complex with a chelator for securely binding radionuclides to targeting molecules, and a binding moiety of targets expressed on tumor cells. Early clinical results have been promising, with […]
Cancer.gov
- In a new National Institutes of Health (NIH)-funded study, scientists at Cleveland Clinic discovered that hormones associated with male development may play a key role in limiting the growth of brain tumors in men. The research team found that the loss of androgen hormones, such as testosterone, in a preclinical model of glioblastoma drove tumor […]
- In a National Institutes of Health (NIH)-funded study, researchers developed a cancer assessment tool that can identify high-risk patients and the tumor cells linked to that risk. The model, called scSurvival, uses a machine learning framework designed to analyze large-scale data at single-cell resolution.
- In a new study, funded in part by the National Institutes of Health (NIH), researchers have uncovered a molecular mechanism that could explain how chronic gut inflammation may increase the risk of colorectal cancer. By simulating chronic colitis in mice and tracking the colon’s response during inflammation and recovery, scientists demonstrated that these changes increased […]
- National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer. The new test could improve survival rates from pancreatic cancer, which tends to be diagnosed at late stages when therapy is less likely to be effective. The findings were published in Clinical […]
- Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) researchers, identified key factors that drive tumor evolution and influence outcomes. Overall, the findings, published Dec. 10, 2025, in Nature, describe a previously unknown origin of some aggressive lung cancers.
JAMA Oncology – Current Issue
- This prognostic study evaluates the association between circulating tumor DNA–defined molecular residual disease and survival outcomes and whether molecular residual disease status is associated with differential benefit from adjuvant chemotherapy in resected colorectal liver metastases.
- Following the paradigm-changing results of the PACIFIC trial, it was logical to test whether concurrent immune checkpoint inhibitors (ICIs) and thoracic radiotherapy (TRT) would result in superior patient outcomes for patients with locally advanced lung cancer. It is clear that such approaches should be reconsidered.
- This phase 2 randomized clinical evaluates whether combining consolidative thoracic radiotherapy with immunotherapy maintenance in extensive-stage small cell lung cancer overall survival (OS), progression-free survival (PFS), or safety.
- A 56-year-old man had a 10-year history of recurrent, generalized violaceous papules and firm nodules. What is your diagnosis?
- This cross-sectional temporal analysis examines cancer type–specific contributions to the reduction in all-cancer excess mortality rate among Black population compared with White population between the peak period (1991-1995) and a contemporary period (2019-2023) in the US.
ClinicalTrials.gov – Cancer
- Conditions: Autologou; Bone Marrow Transplant Complications Sponsors: Assiut University Not yet recruiting
- Conditions: Advanced Cancer; Cancer Pain; Chronic Pain Interventions: Behavioral: Healing Gardens content development/refinement activities; Behavioral: Healing Gardens serious game Sponsors: Dana-Farber Cancer Institute; National Cancer Institute (NCI) Not yet recruiting
- Conditions: Pancreas Cancer, Metastatic; Pancreas Carcinoma Interventions: Other: STRONG intervention App; Other: individualized remote dietitian Sponsors: UNC Lineberger Comprehensive Cancer Center; United States Department of Defense Not yet recruiting
- Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Indocyanine green; Procedure: Near-infrared fluorescence imaging Sponsors: Washington University School of Medicine Not yet recruiting
- Conditions: Epithelial Ovarian Cancer Interventions: Diagnostic Test: HRD test Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS; AstraZeneca Not yet recruiting
STAT!Ref Evidence Alerts
- J Clin Oncol. 2026 Sep 3:JCO2502974. doi: 10.1200/JCO-25-02974.
- Eur Heart J. 2026 Jul 28:ehag562. doi: 10.1093/eurheartj/ehag562.
- J Clin Oncol. 2026 Jun 4:101200JCO2601029. doi: 10.1200/JCO-26-01029.
- J Clin Oncol. 2026 Jul 2:JCO2502735. doi: 10.1200/JCO-25-02735.
- Lancet Oncol. 2026 Jul 13:S1470-2045(26)00133-6. doi: 10.1016/S1470-2045(26)00133-6.

ACCEL – Professional Insight, always within reach.
Professional Development Insights are part of the Salinas Valley Health’s Medical Staff Services and for our Physicians/APPs, we offer ACCEL.
ACCEL is a professional development platform created exclusively for Physicians and APPs at Salinas Valley Health. It offers expert-led content on the non-clinical aspects of medical practice — the things that shape daily work but rarely fit into formal training. Articles, Book Summaries, Videos, Audio/Visual… just for you!
- Provided at no cost to Medical Staff members
- Optional and self-directed
- Private — not tracked or reported
- Available on any computer or mobile device
- Login and password provided by Medical Staff Services
Here are the Just In insights…
*For providers of Salinas Valley Health, if you need access to any particular article referred to in these news feeds, please email Library@SalinasValleyHealth.com

